ClinicalTrials.gg
CompletedNCT06126575Updated Nov 19, 2024

A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

A Phase 1 interventional study of Elacestrant dihydrochloride in Hepatic Impairment, sponsored by Stemline Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Stemline Therapeutics, Inc. (part of Menarini Group) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.
  • Registered 7 months after the study started (first participant enrolled Mar 2023, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing elacestrant in Breast Neoplasms — 15 open to participants now, 18 under way, 3 of them phase 3. elacestrant · Breast Neoplasms.

Enrollment
22nd of 24
16 · median 72
Started
2023
with 5 others
Phase 1
4 of 24
none open now
Registered
12th of 24
by date
Lead sponsor
9 of 24
Stemline Therapeutics, Inc.

Among the 24 studies testing elacestrant in Breast Neoplasms, this one is the 22nd largest by enrollment, is one of 6 that started in 2023, is one of 4 in phase 1, and was the 12th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 24 studies testing elacestrant in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About elacestrant

elacestrant: first FDA approval 2023 (ORSERDU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing elacestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 1, multi-center, open-label, non-randomized, parallel group study to evaluate the effect of severe hepatic impairment on the PK, safety and tolerability of a single oral dose of Elacestrant.

Read the detailed description

A total of 16 subjects will be recruited and divided between the following two Groups:

Group 1: 8 subjects with severe hepatic impairment Group 2: 8 subjects with normal hepatic function (control group)

On Day 1, subjects will receive a single oral dose of 200 mg Elacestrant (2 x 100 mg tablets). Safety assessment and blood sampling for Elacestrant analysis on plasma will be performed at predefined time points up to 240 hours post.

The total duration of study participation for each subject (from screening to the follow up call) is anticipated to be approximately 6 weeks.

03

Conditions studied

  • Hepatic Impairment

Browse trials for

Keywords

  • metastatic breast cancer
  • breast cancer
  • elacestrant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the study procedures in the form (ICF) and be willing and able to comply with the protocol restrictions and requirements.
  2. Males and Females older than 18 years.
  3. between 18.0 and 40.0 kg/m\^2, inclusive.
  4. Females must have non-functioning ovaries defined as and/or bilateral salpingo - oophorectomy. All female subjects must have a negative pregnancy test at screening and at check-in.
  5. Males who are non-sterilized and sexually active with a female partner of must agree to use highly effective from admission and for 120 days after IMP dose.
  6. Males must agree not to donate sperm from admission and for 120 days after medicinal product dose.
  7. Non-smoker or light smoker, i.e. no more than 10 cigarettes or 10 mg equivalent use of Nicotine per day by e-vapor cigarette, pipe, cigar, chewing tobacco, nicotine patch, nicotine gum, AND able or willing to refrain from smoking and tobacco use for 2 hours prior to dose and 4 hours after IMP dose.

    Additional inclusion criteria applicable to subjects with Normal Hepatic Function Only

  8. In good health, determined by no findings from medical history, physical examination, 12-lead , vital signs measurements, and clinical laboratory evaluations. NOTE: Congenital nonhemolytic hyperbilirubinemia/Gilbert's syndrome based on total and direct is not acceptable.
  9. Matched to subjects with severe hepatic impairment in gender, age (±10 years), weight (±10 kg) and race.

    Additional inclusion criteria applicable to subjects with Severe Hepatic Impairment Only

  10. Documented chronic stable severe liver disease according to (CP) classification (CP score C) with diagnosis of hepatic impairment due to parenchymal liver disease. This will exclude biliary liver cirrhosis or other causes of hepatic impairment not related to parenchymal disorder.

    • 'Documented' is defined by medical history and physical examination, and confirmed by at least 1 of the following: hepatic ultrasound, computed axial tomography scan, magnetic resonance imaging, and/or liver .
    • 'Chronic' is defined as >6 months.
    • 'Stable' is defined as no clinically significant change in disease status within the last 6 weeks, as documented by the subject's recent medical history (eg, no worsening of clinical signs of hepatic impairment, or no worsening of total bilirubin or by more than 50%).
  11. Subjects with severe hepatic impairment may have medical findings consistent with their hepatic dysfunction as determined by medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations at screening and check-in (Day -1), as assessed by the Investigator, provided that the followings are satisfied:

    • Non-hepatic impairment-related, abnormal clinical laboratory evaluations must not be clinically relevant, as judged by the Investigator and approved by the study assigned medical monitor.
    • Values outside the normal ranges for liver function tests are acceptable as consistent with the subject's hepatic condition, provided they are stable for at least 1 month prior to screening, as judged by the Investigator and approved by the study assigned medical monitor.
    • Subjects may enter with non-clinically significant Grade 1 anemia per version 5.0, i.e. with > 10 mg/dL.
    • Subjects must have a count ≥ 35 × 109 /L
  12. Subjects with stable, mild, chronic concurrent diseases, such as degenerative joint disease, hypertension or hyperlipidaemia, etc. may be included. Subjects with diabetes mellitus may be included, provided the subjects have:

    • Glycosylated values ≤ 9.5% at screening; eligibility in case of outside values should be evaluated by the study assigned medical monitor on a case-by-case basis.
    • Blood glucose values ≤ 240 mg/dL at screening and check-in (Day -1) while on subjects' normal diabetes medication.
  13. Currently on a stable medication regimen, defined as not starting new drug(s) or changing drug dose(s) within 28 days of administration of study drug (Day 1). Concomitant medications administered within 28 days prior to administration of study drug (Day 1) must be approved by the Investigator and the study assigned medical monitor.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any condition or circumstance that prevents the subject from understanding and signing the ICF.
  2. Presence or history of any disorder that may prevent the successful completion of the study.
  3. History of significant , intolerance, or allergy to food, or any medical product or relevant , unless approved by the Investigator.
  4. History of allergy to Elacestrant or drugs in a similar pharmacology class (selective ER modulator or SERD) or excipients used in the formulations of these drugs.
  5. History of stomach or intestinal surgery or resection, or any significant gastrointestinal disease (eg, Crohn's disease) that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed). Cholecystectomy will be allowed at the discretion of the Investigator.
  6. Acute disease state (eg, nausea, vomiting, fever, diarrhea) within 14 days prior to check-in.
  7. History of drug/chemical abuse within 1 year prior to check-in.
  8. History of alcohol abuse within 3 months prior to screening and/or consume > 21 units per week for males and > 14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1 1⁄2 oz (45 mL) liquor, or 5 oz (150 mL) wine.
  9. Positive drug screen at screening, or positive alcohol or drug screen at check-in.
  10. Participation in a clinical study involving administration of an drug (new chemical entity) or device in the past 28 days or 5 half-lives (whichever is longer) prior to dosing.
  11. Received Elacestrant within 60 days prior to dosing.
  12. Corrected value of the interval between the Q and T waves on the tracing, using Fridericia's formula, is > 450 ms (for healthy males) or > 470 ms (for healthy females), is > 470 ms (for hepatic impairment males) or > 480 ms (for hepatic impairment females); or has ECG findings deemed abnormal with clinical significance by the Investigator at screening. ECGs will be collected in triplicate.
  13. Use of any drugs or herbal remedies known to be strong or moderate inhibitors or inducers of enzymes for 28 days prior to dosing or 5 half-lives (whichever is longer) and throughout the study.
  14. Not willing to follow on-study diet requirements.
  15. Ingestion of Seville orange- or grapefruit- containing foods or beverages within 28 days prior to check-in.
  16. Receipt of blood products within 2 months prior to check-in.
  17. Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or from 6 weeks prior to screening.
  18. Poor peripheral venous access.
  19. Subjects who, in the opinion of the Investigator, should not participate in this study.

    Additional exclusion criteria applicable to Subjects with Normal Hepatic Function Only

  20. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular (including any prior history of cardiomyopathy or cardiac failure), gastrointestinal, neurological, or psychiatric disorder.
  21. Unable to refrain from or anticipate the use of any non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to dosing and throughout the study.

    NOTE: After check-in, acetaminophen (up to 2 g per 24 hours), and 1% hydrocortisone cream may be administered at the discretion of the Investigator.

  22. Unable to refrain from or anticipate the use of any prescription medications within 28 days prior to dosing or 5 half-lives (whichever is longer) and throughout the study, unless approved by the Investigator and the study assigned medical monitor.

    NOTE: slow-release medications / products considered to still be active prior to check-in must be approved by the Investigator and the study assigned medical monitor.

  23. Positive panel test and/or positive RNA test. Subjects whose results are compatible with prior immunization may be included.
  24. History of diabetes mellitus.

    Additional exclusion criteria applicable to Subjects with Hepatic Impairment Only

  25. Grade 3 and Grade 4 encephalopathy as determined by the CP score.
  26. Portal systemic shunt.
  27. Subject has shown evidence of hepatorenal syndrome or abnormal serum creatinine levels (above upper limit for the local lab) and estimated \< 60 mL/min or abnormal sodium and potassium levels. The determination of the severity and clinical relevance of the latter 2 abnormalities will be at the discretion of the Investigator.
  28. Treatment for gastrointestinal bleeding within the 3 months prior to check-in.
  29. New medication or a change in dose for hepatic encephalopathy within the 3 months prior to check-in, unless approved by the Investigator and the study assigned medical monitor.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Subjects with normal hepatic function

    Subjects with normal hepatic function will receive treatment compared to subjects with severe hepatic function

    Drug: Elacestrant dihydrochloride

  • Experimental
    Subjects with severe hepatic impaired function

    Subjects with severe hepatic function will receive treatment compared to subjects with normal hepatic function

    Drug: Elacestrant dihydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Predose 240 hours after drug administration

  2. Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t)

    Time frame: Predose 240 hours after drug administration

  3. AUC from time zero to infinity (AUC0-∞)

    Time frame: Predose 240 hours after drug administration

07

Study locations

3 sites
  • Inland Empire Clinical Trials, LLC
    Yucaipa, California 92399, United States
  • Floridian Clinical Research
    Miami, Florida 33016, United States
  • American Research Corp
    San Antonio, Texas 78215, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Nov 2024, 19 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 19 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2023
First posted
Nov 13, 2023
StartActual
Mar 13, 2023
Primary completionActual
Nov 11, 2024
CompletionActual
Nov 11, 2024
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06126575
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Mar 13, 2023
Primary completion
Nov 11, 2024
Completion
Nov 11, 2024
Last update
Nov 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elacestrant

Start the discussion